Follow The Filings

Pfizer Inc.

New York, NY 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

  • $170M
  • 17 holdings
  • 2026 Q2
  • −28.9% QoQ
  • Top 5 78.9%

Pfizer's biggest moves in 2026 Q2 were trimming Oric Pharmaceuticals and Zura Bio, and selling out of Q32 Bio.

Portfolio

2026 Q2, filed 8/13/2026, top 12 of 17 holdings

Top 5 78.9%, top 10 95.7%

AUM over time

2026 Q2 $170M −28.9% QoQ
2025 Q3: $437M 2025 Q3: $437M
Q3 2025
2025 Q4: $236M, −46.0% QoQ 2025 Q4: $236M, −46.0% QoQ
Q4
2026 Q1: $239M, +1.3% QoQ 2026 Q1: $239M, +1.3% QoQ
Q1 2026
2026 Q2: $170M, −28.9% QoQ 2026 Q2: $170M, −28.9% QoQ
Q2

Latest book

2026 Q2 2026 Q1, filed 13 Aug, long equity only

ALLO, Allogene Therapeutics 27.55% Hold 22,032,040 $2.13 $47M — —
CELC, Celcuity 17.35% Hold 295,652 $99.95 $30M — —
ARVN, Arvinas 16.24% Hold 3,457,815 $8.00 $28M — —
PYXS, Pyxis Oncology 11.43% Hold 7,032,770 $2.77 $19M — —
WVE, Wave Life Sciences 6.42% Hold 1,875,000 $5.83 $11M — —
BHVN, Biohaven 4.70% Hold 505,645 $15.83 $8M — —
CRBU, Caribou Biosciences 4.63% Hold 4,690,431 $1.68 $7.9M — —
Spero Therapeutics 3.13% Hold 2,362,348 $2.26 $5.3M — —
ZNTL, Zentalis Pharmaceuticals 2.26% Hold 953,834 $4.04 $3.9M — —
ORIC, Oric Pharmaceuticals 2.09%, was 24.14% Reduce −92.2% 372,904 $9.53 $3.6M −4,407,497 −$54M
CRDF, Cardiff Oncology 1.77% Hold 2,411,575 $1.25 $3M — —
ZURA, Zura Bio 1.69%, was 7.05% Reduce −81.0% 538,841 $5.35 $2.9M −2,300,072 −$14M
AGMB, Agomab Therapeutics 0.61% Hold 75,000 $13.81 $1M — —
BOLT, Bolt Biotherapeutics 0.08% Hold 31,305 $4.28 $134K — —
NXTC, Nextcure 0.04%, was 0.64% Reduce −71.1% 44,347 $1.65 $73K −109,007 −$1.5M
DNA, Ginkgo Bioworks 0.02% Hold 2,928 $10.25 $30K — —
Senseonics 0.01% Hold 2,171 $5.72 $12K — —

Exits / last held

Gone since 2026 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
QTTB, Q32 Bio 0.31% Exit 0 $7.25 $737K −101,618 −$737K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2026 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

4 periods, with AUM normalized

Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 17 $170M −28.9% 13F-HR 8/13/2026 000007800326000102
2026 Q1 18 $239M +1.3% 13F-HR 5/12/2026 000007800326000064
2025 Q4 18 $236M −46.0% 13F-HR 2/12/2026 000007800326000013
2025 Q3 21 $437M — 13F-HR 11/13/2025 000007800325000161

About

Pfizer Inc.

4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

SEC filing name
PFIZER INC
Location
New York, NY
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf